Pulmonary System Articles & Analysis
18 news found
” Over 600,000 Japanese patients suffer from severe COPD, including approximately 100,000 patients with severe disease where hyperinflation causes them to remain symptomatic despite adhering to their medications, doing pulmonary rehabilitation, and using supplemental oxygen.2 Hyperinflation, in which air becomes trapped in the lungs and prevents new air from coming in, ...
Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. ...
Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. ...
AoP is a common developmental disorder within pre-term births attributed to immaturity of the pulmonary system characterized by either cessation of breathing for more than 20 seconds or cessation of breathing that lasts less than 20 seconds but is accompanied by either bradycardia or hypoxemia. ...
Data on the first 40 patients in the study demonstrated that treatment with the AeriSeal System successfully converted the collateral ventilation (CV) status in 78% of patients who were subsequently treated with Zephyr Valves. ...
Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. ...
INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ...
INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ...
Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced positive data from the SIRONA 2 clinical trial evaluating safety and efficacy of its Cordella™ Pulmonary Artery Pressure Sensor System (Cordella Sensor) in New York Heart Association (NYHA) class III heart failure ...
INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ...
Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. ...
INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ...
The compound utilizes the body's own ventilation control system to beneficially influence breathing and has been shown to be effective and well-tolerated in four previous human studies. About Apnea of Prematurity Apnea of Prematurity is a development disorder attributed to immaturity of the pulmonary system characterized by either cessation of ...
The trial is a pre-market investigational device exempt (IDE) study evaluating the safety and efficacy of the Cordella™ Pulmonary Artery (PA) Pressure Sensor System (Cordella Sensor) for the treatment of HF. ...
-based Endotronix, Inc. and Tyndall will explore the application of novel electronics technologies to wireless, implantable sensors for chronic disease management, such as the Cordella Pulmonary Artery Pressure Sensor System (Cordella Sensor). “Together our Cordella Sensor and Cordella System provide a robust platform for data-guided ...
The funds will be used to support the landmark PROACTIVE-HF IDE clinical trial of the Cordella Pulmonary Artery Sensor System (Cordella Sensor) and commercialization of the Cordella Heart Failure System (Cordella System). ...
The 60-patient study will evaluate safety and efficacy of the Cordella™ Pulmonary Artery Pressure Sensor System (Cordella Sensor) in support of its CE Mark submission. ...
The criteria define MCS as symptoms that are reproducible with repeated chemical exposure, are chronic, appear at levels of exposure lower than previously tolerated, improve or resolve when incitants are removed, appear in response to multiple chemically unrelated substances, and which involve multiple organ systems that commonly include the cardiac, pulmonary, ...